Lynn T. Tanoue

Disclosures

Curr Opin Pulm Med. 2016;22(4):327-335. 

In This Article

Conclusion

Demonstrating mortality benefit with lung cancer screening is an enormous advance in the field. This approach to early detection is still imperfect; the false-positive rate is too high, the potential for related harm very real, and benefit will be limited to those individuals who meet the criteria of the USPSTF recommendation. Education and informed decision-making are necessary and integral parts of the screening process, as both providers and patients must appreciate potential benefits and risks. Much work remains to be done to improve the evaluation and management of screen-detected pulmonary nodules, to minimize the consequences of evaluation for false-positive results, and to refine the tools used to identify populations at risk as well as to guide the management of individuals with positive screening results.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....